For the stated reasons above, U.S. pharmaceutical company Patient Assistance Programs (PAPs) should be an integral part of the new, reformed health care system currently being debated in Congress. U.S. pharmaceutical companies have offered these programs for years, so there should be no debate as to their assistance to low income uninsured Americans. By integrating and expanding PAPs in the current health care environment the overall cost to taxpayers will be reduced.
PAPs are highly relevant in the current health care debate. By expanding their use and coverage, they will enable other reforms to be made. U.S. pharmaceutical companies absorb the costs of these programs, so there is no taxpayer money involved.